[{"id":"eb5c9ee3-620e-48d0-bab8-f8f2914ede1d","acronym":"NRG-BN010","url":"https://clinicaltrials.gov/study/NCT04729959","created_at":"2021-03-09T19:55:01.650Z","updated_at":"2024-07-02T16:34:27.180Z","phase":"Phase 2","brief_title":"Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma","source_id_and_acronym":"NCT04729959 - NRG-BN010","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • MGMT • TERT","pipe":" | ","alterations":" EGFR amplification • TERT mutation • IDH wild-type • TERT promoter mutation","tags":["EGFR • MGMT • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • TERT mutation • IDH wild-type • TERT promoter mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Actemra IV (tocilizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 03/11/2022","start_date":" 03/11/2022","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-06-11"},{"id":"8fd31dd0-c717-4033-9f44-afbf209f365e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04225039","created_at":"2021-03-09T19:53:36.498Z","updated_at":"2024-07-02T16:35:12.728Z","phase":"Phase 2","brief_title":"Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma","source_id_and_acronym":"NCT04225039","lead_sponsor":"University of Pennsylvania","biomarkers":" MGMT • TERT","pipe":" | ","alterations":" EGFR amplification • TERT mutation • IDH wild-type • TERT promoter mutation","tags":["MGMT • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • TERT mutation • IDH wild-type • TERT promoter mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • ragifilimab (INCAGN1876)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 06/23/2020","start_date":" 06/23/2020","primary_txt":" Primary completion: 09/08/2022","primary_completion_date":" 09/08/2022","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-03-26"},{"id":"50f8b205-06c7-4e3e-b459-1ebbfce2f273","acronym":"","url":"https://clinicaltrials.gov/study/NCT04910022","created_at":"2021-06-02T20:57:18.421Z","updated_at":"2024-07-02T16:35:14.620Z","phase":"Phase 1/2","brief_title":"Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma","source_id_and_acronym":"NCT04910022","lead_sponsor":"Nerviano Medical Sciences","biomarkers":" EGFR • IDH1 • IDH2 • MGMT • TERT","pipe":" | ","alterations":" EGFR mutation • EGFR amplification • MGMT promoter methylation • TERT mutation • IDH wild-type • TERT promoter mutation","tags":["EGFR • IDH1 • IDH2 • MGMT • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR amplification • MGMT promoter methylation • TERT mutation • IDH wild-type • TERT promoter mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • lomustine • itareparib (NMS-293)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-03-15"},{"id":"9ac5a259-2a1d-4705-a42a-0a8634a71850","acronym":"","url":"https://clinicaltrials.gov/study/NCT06236464","created_at":"2024-02-01T18:21:37.212Z","updated_at":"2024-07-02T16:35:21.338Z","phase":"","brief_title":"Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas","source_id_and_acronym":"NCT06236464","lead_sponsor":"National Cancer Institute, Naples","biomarkers":" TERT","pipe":" | ","alterations":" TERT mutation • TERT promoter mutation","tags":["TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TERT mutation • TERT promoter mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 09/25/2023","start_date":" 09/25/2023","primary_txt":" Primary completion: 11/19/2025","primary_completion_date":" 11/19/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-02-01"},{"id":"1e7d842e-e4ca-4d95-b896-1da6f52d2d98","acronym":"","url":"https://clinicaltrials.gov/study/NCT03726515","created_at":"2021-01-18T18:15:36.195Z","updated_at":"2024-07-02T16:35:44.942Z","phase":"Phase 1","brief_title":"CART-EGFRvIII + Pembrolizumab in GBM","source_id_and_acronym":"NCT03726515","lead_sponsor":"University of Pennsylvania","biomarkers":" EGFR • MGMT • TERT","pipe":" | ","alterations":" EGFR amplification • MGMT promoter methylation • TERT mutation • EGFRvIII expression • IDH wild-type • TERT promoter mutation","tags":["EGFR • MGMT • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • MGMT promoter methylation • TERT mutation • EGFRvIII expression • IDH wild-type • TERT promoter mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • LXF821"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 03/11/2019","start_date":" 03/11/2019","primary_txt":" Primary completion: 02/27/2021","primary_completion_date":" 02/27/2021","study_txt":" Completion: 02/27/2021","study_completion_date":" 02/27/2021","last_update_posted":"2023-06-22"},{"id":"6f24da17-d18e-4f79-befe-3764e25c2b19","acronym":"","url":"https://clinicaltrials.gov/study/NCT05271240","created_at":"2022-03-08T16:52:43.604Z","updated_at":"2024-07-02T16:35:47.014Z","phase":"Phase 3","brief_title":"Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM","source_id_and_acronym":"NCT05271240","lead_sponsor":"Northwell Health","biomarkers":" EGFR • TERT","pipe":" | ","alterations":" EGFR mutation • EGFR amplification • TERT mutation • IDH wild-type • TERT promoter mutation","tags":["EGFR • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR amplification • TERT mutation • IDH wild-type • TERT promoter mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • temozolomide"],"overall_status":"Recruiting","enrollment":" Enrollment 432","initiation":"Initiation: 04/27/2022","start_date":" 04/27/2022","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2023-05-29"},{"id":"9281feb2-76be-43ef-aaa8-b34124c78001","acronym":"","url":"https://clinicaltrials.gov/study/NCT04924127","created_at":"2021-06-11T18:56:22.686Z","updated_at":"2024-07-02T16:35:50.094Z","phase":"","brief_title":"Molecular Pathology Research Project of Glioma","source_id_and_acronym":"NCT04924127","lead_sponsor":"Jinsong Wu","biomarkers":" TERT","pipe":" | ","alterations":" TERT mutation • TERT promoter mutation","tags":["TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TERT mutation • TERT promoter mutation"],"overall_status":"Completed","enrollment":" Enrollment 976","initiation":"Initiation: 12/05/2019","start_date":" 12/05/2019","primary_txt":" Primary completion: 06/06/2021","primary_completion_date":" 06/06/2021","study_txt":" Completion: 12/20/2021","study_completion_date":" 12/20/2021","last_update_posted":"2023-04-19"},{"id":"cc53a890-89ed-4959-a512-acb62dcd9222","acronym":"HELP-2020","url":"https://clinicaltrials.gov/study/NCT04506398","created_at":"2021-06-24T18:52:50.426Z","updated_at":"2024-07-02T16:36:28.684Z","phase":"","brief_title":"Heterogeneity and Evolution of hepatoceLlular Carcinoma in Post-transplant HCC Recurrence","source_id_and_acronym":"NCT04506398 - HELP-2020","lead_sponsor":"RenJi Hospital","biomarkers":" TP53 • TERT • CCND1 • IL6 • FGF19 • TGFB1 • AXIN1 • RPS6KA3","pipe":" | ","alterations":" CTNNB1 mutation • TERT mutation • TERT promoter mutation","tags":["TP53 • TERT • CCND1 • IL6 • FGF19 • TGFB1 • AXIN1 • RPS6KA3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTNNB1 mutation • TERT mutation • TERT promoter mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 09/10/2020","start_date":" 09/10/2020","primary_txt":" Primary completion: 08/01/2021","primary_completion_date":" 08/01/2021","study_txt":" Completion: 08/01/2022","study_completion_date":" 08/01/2022","last_update_posted":"2021-06-24"},{"id":"09b798c5-a6f6-44d0-968a-d13396500709","acronym":"","url":"https://clinicaltrials.gov/study/NCT02766270","created_at":"2021-01-18T13:33:56.349Z","updated_at":"2024-07-02T16:37:26.356Z","phase":"Phase 1","brief_title":"CCRT With Temozolomide Versus RT Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas","source_id_and_acronym":"NCT02766270","lead_sponsor":"Beijing Tiantan Hospital","biomarkers":" TERT","pipe":" | ","alterations":" TERT mutation • IDH wild-type • TERT promoter mutation","tags":["TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TERT mutation • IDH wild-type • TERT promoter mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 09/26/2016","start_date":" 09/26/2016","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2017-01-20"}]